We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Pathogens Rapidly Identified by Novel Molecular Methods

By LabMedica International staff writers
Posted on 12 Nov 2013
Rapid and accurate identification of pathogens responsible for sepsis, a life-threatening medical condition that is defined as systemic inflammatory response syndrome, is essential for early and targeted antimicrobial therapy.

Blood cultures represent the reference standard for the detection and identification of pathogens that cause bloodstream infections but conventional culture-based identification systems are time consuming but can be improved by using additional test systems.

Microbiologists at the Medical University of Graz (Austria) examined 103 positive blood cultures collected from December 2012 until March 2013. More...
Blood cultures were obtained from patients with suspected sepsis as part of the standard hospital care and transferred to the laboratories.

The investigators evaluated the hemoFISH test using Beacon-Based Fluorescence in Situ Hybridization (bbFISH) technology for accurate identification of microorganisms in positive blood cultures by comparison with culture-based identification methods. The hemoFISH assay (miacom diagnostics, Inc.; Düsseldorf, Germany) is an in vitro diagnostic/Conformité Européene (CE) labeled test system that uses the bbFISH technology.

A total number of 103 positive blood culture bottles, with 59.0% grown in BACTEC Plus Aerobic/F and 41.0% BACTEC Plus Anaerobic/F (Becton Dickinson Diagnostic Systems; Franklin Lakes, NJ, USA), were tested. Culture-dependent identification with the use of the reference methods of mass spectrometry (MALDI-TOF MS Shimatzu Corporation; Kyoto, Japan) or Vitek2 (bioMérieux; Marcyl`Etoile, France) indicated that 95.1% of the blood culture bottles showed monomicrobial growth and 4.9% showed polymicrobial growth.

From the 106 bacterial species identified with the reference methods, the hemoFISH correctly identified 55.7% to species level, 34.0% to genus level, 7.5% to family level, and 2.8% were unidentifiable. The hemoFISH assay showed a sensitivity and specificity of 100%. From the 106 slides tested, in 11 cases the readout was initially challenging because of slight autofluorescence from certain probes. These slides were reevaluated and double-checked by a second investigator. In all cases, the result obtained by the two investigators was in agreement with the culture results. The specific fluorescence was much brighter than the observed autofluorescence.

The authors concluded that the hemoFISH assay that uses the novel bbFISH technology is an easy-to-handle, rapid, reliable tool for the identification of a broad range of microorganisms and facilitates the decision of antimicrobial therapy in septic patients. The study was published in the November 2013 issue of the Journal of Molecular Diagnostics.

Related Links:

Medical University of Graz
miacom diagnostics
Becton Dickinson Diagnostic Systems 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Platelet Function Analyzer
PL-12
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.